Department of Biology, Massachusetts Institute for Technology, Cambridge, MA 02139; Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA.
Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA; Blavatnik Institute, Genetics Department, Harvard Medical School, Boston, MA 02115, USA.
Cell Metab. 2024 Feb 6;36(2):354-376. doi: 10.1016/j.cmet.2023.12.007. Epub 2024 Jan 4.
Here, we summarize the current knowledge on eight promising drugs and natural compounds that have been tested in the clinic: metformin, NAD precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics, probiotics, and anti-inflammatories. Multiple clinical trials have commenced to evaluate the efficacy of such agents against age-associated diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases. There are reasonable expectations that drugs able to decelerate or reverse aging processes will also exert broad disease-preventing or -attenuating effects. Hence, the outcome of past, ongoing, and future disease-specific trials may pave the way to the development of new anti-aging medicines. Drugs approved for specific disease indications may subsequently be repurposed for the treatment of organism-wide aging consequences.
在这里，我们总结了目前在临床上进行测试的 8 种有前途的药物和天然化合物的知识：二甲双胍、NAD 前体、胰高血糖素样肽-1 受体激动剂、TORC1 抑制剂、亚精胺、衰老细胞清除剂、益生菌和抗炎药。多项临床试验已经开始评估这些药物对包括糖尿病、心血管疾病、癌症和神经退行性疾病在内的与年龄相关疾病的疗效。有合理的期望认为，能够减缓或逆转衰老过程的药物也将产生广泛的疾病预防或减轻效果。因此，过去、正在进行和未来的特定疾病试验的结果可能为开发新的抗衰老药物铺平道路。针对特定疾病适应症批准的药物随后可能被重新用于治疗全身性衰老的后果。
